| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 343 | 2019 |
| Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions M Ralli, A Botticelli, IC Visconti, D Angeletti, M Fiore, P Marchetti, ... Journal of immunology research 2020 (1), 9235638, 2020 | 187 | 2020 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 172 | 2020 |
| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 163 | 2020 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 158 | 2019 |
| Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment A Botticelli, P Vernocchi, F Marini, A Quagliariello, B Cerbelli, S Reddel, ... Journal of translational medicine 18, 1-10, 2020 | 144 | 2020 |
| Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? A Botticelli, B Cerbelli, L Lionetto, I Zizzari, M Salati, A Pisano, M Federica, ... Journal of translational medicine 16, 1-6, 2018 | 113 | 2018 |
| Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer P Vernocchi, T Gili, F Conte, F Del Chierico, G Conta, A Miccheli, ... International Journal of Molecular Sciences 21 (22), 8730, 2020 | 98 | 2020 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 97 | 2020 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 96 | 2021 |
| The sexist behaviour of immune checkpoint inhibitors in cancer therapy? A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ... Oncotarget 8 (59), 99336, 2017 | 94 | 2017 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 92 | 2021 |
| Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma A Baggi, P Quaglino, M Rubatto, R Depenni, M Guida, PA Ascierto, ... European Journal of Cancer 157, 250-258, 2021 | 76 | 2021 |
| Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents A Rossi, M Roberto, M Panebianco, A Botticelli, F Mazzuca, P Marchetti European journal of pharmacology 862, 172621, 2019 | 76 | 2019 |
| A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience P Vici, L Pizzuti, A Michelotti, I Sperduti, C Natoli, L Mentuccia, L Di Lauro, ... Oncotarget 8 (34), 56921, 2017 | 72 | 2017 |
| Anti–PD-1 and anti–PD-L1 in head and neck cancer: a network meta-analysis A Botticelli, A Cirillo, L Strigari, F Valentini, B Cerbelli, S Scagnoli, ... Frontiers in immunology 12, 705096, 2021 | 65 | 2021 |
| Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis M Ghidini, G Tomasello, A Botticelli, S Barni, G Zabbialini, S Seghezzi, ... Hpb 19 (9), 741-748, 2017 | 64 | 2017 |
| Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment A Botticelli, I Zizzari, F Mazzuca, PA Ascierto, L Putignani, L Marchetti, ... Oncotarget 8 (5), 8890, 2017 | 64 | 2017 |
| PD‐L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy? B Cerbelli, A Pernazza, A Botticelli, L Fortunato, M Monti, P Sciattella, ... BioMed research international 2017 (1), 1750925, 2017 | 63 | 2017 |
| Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti, ... The pharmacogenomics journal 16 (4), 320-325, 2016 | 62 | 2016 |
